collbl,Dipeptidyl peptidase 4 (DPP-4) inhibitors_agg,Dipeptidyl peptidase 4 (DPP-4) inhibitors_ipd,Glucagon-like peptide-1 (GLP-1) analogues_agg,Glucagon-like peptide-1 (GLP-1) analogues_ipd,Sodium-glucose co-transporter 2 (SGLT2) inhibitors_agg,Sodium-glucose co-transporter 2 (SGLT2) inhibitors_ipd,Total trials_agg,Total trials_ipd
Trials,237,43,158,34,140,32,489,103
2 arms,204,27,106,22,107,12,388,56
3 arms,25,10,41,9,28,16,80,34
4 or 5 arms,8,6,11,3,5,4,21,13
Participants,109293,29991,79184,28137,44039,40191,217321,92182
Male,63066 (57.7%),16724 (55.8%),44780 (56.6%),16309 (58.0%),24776 (56.3%),24638 (61.3%),124159 (57.1%),54465 (59.1%)
Age,58.8 (10.8) [40.3-75.7],57.2 (11.2) [36.9-75.1],57.9 (10.4) [40.4-74.3],59.3 (11.0) [40.0-76.1],61.4 (10.7) [42.9-78.2],57.8 (11.2) [36.4-75.2],59.1 (10.7) [40.9-76.0],58.3 (11.2) [37.6-75.6]
Duration,24.0 (12.0-54.4),24.0 (12.2-53.8),26.0 (12.0-56.0),26.0 (24.0-52.0),24.0 (12.0-52.0),25.0 (17.1-239.2),24.0 (12.0-56.0),24.0 (14.2-104.0)
